Biblio

Found 29 results
[ Author(Asc)] Keyword Title Type Year
Filters: First Letter Of Last Name is G  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
G
Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial., Lancet, vol. 360, no. 9332, pp. 505-15, 2002.
I. Collaborat Group, Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial, Lancet, vol. 360, pp. 505-15, 2002.
B. Gronlund, Hansen, H. H., Hogdall, C., Hogdall, E. V., and Engelholm, S. A., Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?, Br J Cancer, vol. 90, pp. 377-82, 2004.
B. Gronlund, Hogdall, E. V., Christensen, I. J., Johansen, J. S., Norgaard-Pedersen, B., Engelholm, S. A., and Hogdall, C., Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA 125), Int J Biol Markers, vol. 21, pp. 141-8, 2006.
B. Gronlund, Hogdall, C., Hilden, J., Engelholm, S. A., Hogdall, E. V., and Hansen, H. H., Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?, J Clin Oncol, vol. 22, pp. 4051-8, 2004.
P. Grigsby, Winter, K., Komaki, R., Marcial, V., Eifel, P. J., Doncals, D., Stevens, R., Rotman, M., and Gaffney, D. K., Long-term follow-up of RTOG 88-05: twice-daily external irradiation with brachytherapy for carcinoma of the cervix, Int J Radiat Oncol Biol Phys, vol. 54, pp. 51-7, 2002.
K. Greven, Winter, K., Underhill, K., Fontenesci, J., Cooper, J., and Burke, T., Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer, Gynecol Oncol, vol. 103, pp. 155-9, 2006.
E. Greimel, Bjelic-Radisic, V., Pfisterer, J., Hilpert, F., Daghofer, F., Pujade-Lauraine, E., du Bois, A., Group, A. Gynaekolog, and de l'Ovaire, Gd'Investig, Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trials, Support Care Cancer, vol. 19, pp. 1421-7, 2011.
E. Greimel, Kristensen, G. B., van der Burg, M. E. L., Coronado, P., Rustin, G. J. S., del Rio, A. Sanchez, Reed, N. Simon, Nordal, R. R., Coens, C., and Vergote, I. B., Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy., Gynecol Oncol, vol. 131, no. 2, pp. 437-44, 2013.
J. A. Green, ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit, Lancet, vol. 362, p. 1334; author reply 1334, 2003.
J. A. Green, F, D., Coens, C., S, L., Vergote, I. B., Eisenhauer, E., Bacon, M., W, C., van der Burg, M. E. L., and Oza, A. M., Prognostic value of clinical and molecular markers in advanced ovarian cancer: importance of residual disease. Translational study using tumor specimens from EORTC 55931/NCIC OV10 phase III randomized clinical trial. , Proc Am Soc Clin Oncol , vol. 23, no. 16S Part 1, 2005.
J. A. Green, ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit., Lancet, vol. 362, no. 9392, p. 1334; author reply 1334, 2003.
C. Gourley, Farley, J., Provencher, D. M., Pignata, S., Mileshkin, L. R., Harter, P., Maenpaa, J. U., Kim, J. - W., Pujade-Lauraine, E., Glasspool, R. M., Ray-Coquard, I., and Gershenson, D., Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas., Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S9-13, 2014.
M. E. Gore, ICON2 trial. UK consensus statement on standard practice for chemotherapy in ovarian cancer, Lancet, vol. 353, pp. 587-8, 1999.
M. E. Gore, Oza, A. M., Rustin, G. J. S., Malfetano, J. H., Calvert, A. H., Clarke-Pearson, D. L., Carmichael, J., Ross, G., Beckman, R. A., and Fields, S. Z., A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer., Eur J Cancer, vol. 38, no. 1, pp. 57-63, 2002.
V. D. Gonzalez, Samusik, N., Chen, T. J., Savig, E. S., Aghaeepour, N., Quigley, D. A., Huang, Y. - W., Giangarrà, V., Borowsky, A. D., Hubbard, N. E., Chen, S. - Y., Han, G., Ashworth, A., Kipps, T. J., Berek, J. S., Nolan, G. P., and Fantl, W. J., Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass Cytometry., Cell Rep, vol. 22, no. 7, pp. 1875-1888, 2018.
T. GM, S, A., M, P., O, A., and JA, III, L., A GOG phase III trial to evaluate maintaining hemoglobin = 120 G/L with erythropoietin during chemoradiation for cervical cancer. , Int J Gynecol Cancer , vol. 16, no. 3, p. 604, 2006.
R. M. Glasspool, Martín, A. González, Millan, D., Lorusso, D., Åvall-Lundqvist, E., Hurteau, J. A., Davis, A., Hilpert, F., Kim, J. - W., Alexandre, J., and Ledermann, J. A., Gynecologic Cancer InterGroup (GCIG) consensus review for squamous cell carcinoma of the ovary., Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S26-9, 2014.
R. M. Glasspool, Brown, R., Gore, M. E., Rustin, G. J. S., McNeish, I. A., Wilson, R. H., Pledge, S., Paul, J., Mackean, M., Hall, G. D., Gabra, H., Halford, S. E., Walker, J. L., Appleton, K., Ullah, R., Kaye, S. B., and Group, S. Gynaecolog, A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer, Br J Cancer, vol. 110, pp. 1923-9, 2014.
L. Gladieff, Ferrero, A., De Rauglaudre, G., Brown, C., Vasey, P. A., Reinthaller, A., Pujade-Lauraine, E., Reed, N. Simon, Lorusso, D., Siena, S., Helland, H., Elit, L., and Mahner, S., Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial., Ann Oncol, vol. 23, no. 5, pp. 1185-9, 2012.
T. J. Perren, Swart, A. Marie, Pfisterer, J., Ledermann, J. A., Lortholary, A., Kristensen, G. B., Carey, M. S., Beale, P., Cervantes, A., and Oza, A. M., . ICON7: A phase III randomised Gynaecologic Cancer InterGroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian, primary peritoneal or fallopia, Ann Oncol , vol. 21, no. Suppl 8, abstr LBA4, 2010.
K. GB, Vergote, I. B., Stuart, G. C. E., JM, delCampo, Kaern, J., M, B., Lopez, A. B., Hirte, H., E, A. - L., E, L., and O, C., First-line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIb-IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A Gynecologic Cancer Intergroup study. Results on overall survival. , Eur Soc Gyn Oncol.
C. M Gainford, Tinker, A., Carter, J., Petru, E., Nicklin, J., Quinn, M., Hammond, I., Elit, L., Lenhard, M., and Friedlander, M. Leonard, Malignant transformation within ovarian dermoid cysts: an audit of treatment received and patient outcomes. an Australia New Zealand gynaecological oncology group (ANZGOG) and gynaecologic cancer intergroup (GCIG) study., Int J Gynecol Cancer, vol. 20, no. 1, pp. 75-81, 2010.
M. C. Gainford, Tinker, A., Carter, J., Petru, E., Nicklin, J., Quinn, M., Hammond, I., Elit, L., Lenhard, M., and Friedlander, M. Leonard, Malignant transformation within ovarian dermoid cysts: an audit of treatment received and patient outcomes. an Australia New Zealand gynaecological oncology group (ANZGOG) and gynaecologic cancer intergroup (GCIG) study, Int J Gynecol Cancer, vol. 20, pp. 75-81, 2010.
D. K. Gaffney, Hashibe, M., Kepka, D., Maurer, K. A., and Werner, T. L., Too many women are dying from cervix cancer: Problems and solutions., Gynecol Oncol, 2018.

Pages